| Literature DB >> 32741476 |
James MacFarlane1, Waiel A Bashari1, Russell Senanayake1, Daniel Gillett2, Merel van der Meulen1, Andrew S Powlson1, Angelos Kolias3, Olympia Koulouri1, Mark Gurnell4.
Abstract
In most patients with pituitary adenomas magnetic resonance imaging (MRI) is essential to guide effective decision-making. T1- and T2-weighted sequences allow the majority of adenomas to be readily identified. Supplementary MR sequences (e.g. FLAIR; MR angiography) may also help inform surgery. However, in some patients MRI findings are 'negative' or equivocal (e.g. with failure to reliably identify a microadenoma or to distinguish postoperative change from residual/recurrent disease). Molecular imaging [e.g. 11C-methionine PET/CT coregistered with volumetric MRI (Met-PET/MRCR)] may allow accurate localisation of the site of de novo or persistent disease to guide definitive treatment (e.g. surgery or radiosurgery).Entities:
Keywords: (11)C-methionine; MRI; Met-PET/MR(CR); PET/CT; Pituitary adenoma
Mesh:
Year: 2020 PMID: 32741476 DOI: 10.1016/j.ecl.2020.06.002
Source DB: PubMed Journal: Endocrinol Metab Clin North Am ISSN: 0889-8529 Impact factor: 4.741